Clinical trials: SARS CoV 2 Virus
COVID-19
Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness
The purpose of this study is to determine whether nitazoxanide (NTZ) is safe and effective in treating mild or moderate COVID-19 illness in adults and adolescents at highest risk for severe outcomes.
- Trial name
- NCT05157243
- Testing
- Nitazoxanide, Vitamin Super-B Complex, Standard of Care
- Sponsor
- Romark Laboratories L.C.
COVID-19
Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine (IN-B009) in Healthy Adults (COVID-19)
This is a first in human, phase I, open-label, dose-escalation study to assess the safety, reactogenicity, and immunogenicity of a SARS-CoV-2 Vaccine (IN-B009) in healthy adults.
- Trial name
- NCT05113849
- Testing
- IN-B009 (Low-dose), IN-B009 (High-dose)
- Where
- 3 sites in South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Influenza A, Influenza B
Covid Flu A/B and RSV 4 in 1 Diagnostic Test
The goal of this observational study is to evaluate the diagnostic performance of an investigational Flu A/B, COVID-19 and RSV test in patients with signs and symptoms of respiratory infection.
- Conditions
- Influenza A, Influenza B, COVID - 19, RSV
- Trial name
- NCT07308158
- Testing
- Investigational Flu A/B Covid-19 and RSV Diagnostic Test
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 1,119 people
- Sponsor
- iHealth Labs inc
COVID-19, SARS-CoV-2
Ivermectin to Prevent SARS-CoV-2 (COVID-19) Hospitalisation in Subjects Over 50
The primary objective of this study is to assess the efficacy of early administration of ivermectin for three consecutive days to prevent SARS-CoV-2 hospitalisation in adults older than 50 years of age.
- Trial name
- NCT05993143
- Testing
- Ivermectin
- Where
- 20 sites in Spain
- Volunteers
- 249 people
- Sponsor
- Insud Pharma
COVID-19
Evaluate Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19 in China
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Individuals Infected with SARS-CoV-2 in China
- Trial name
- NCT05682599
- Testing
- Azvudine
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Shanghai Henlius Biotech
COVID-19
Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)
This study is a double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of FB2001 in hospitalized patients with moderate to severe Coronavirus Disease 2019 (COVID-19).
- Trial name
- NCT05445934
- Testing
- FB2001
- Where
- 2 sites in China
- Volunteers
- 1,188 people
- Sponsor
- Frontier Biotechnologies Inc.
COVID-19
Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)
This study will investigate how ensovibep is distributed throughout the body, the safety and the tolerability of ensovibep in healthy volunteers
- Trial name
- NCT04870164
- Testing
- Ensovibep
- Where
- United Kingdom
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Molecular Partners AG
SARS-CoV-2 Infection
Dose, Safety and Pathogenicity of SARS-CoV-2 (COVID-19) Omicron Virus (BA.5)
An Exploratory Study to Establish the Dose, Safety and Pathogenicity of a SARS-CoV-2 Omicron Challenge Strain (BA.5) in Healthy Participants 18 to 40 Years of Age
- Trial name
- NCT06492564
- Testing
- SARS-CoV-2 omicron virus dose arm 1, SARS-CoV-2 omicron virus dose arm 2, SARS-CoV-2 omicron virus dose arm 3
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Hvivo
COVID-19
Study of Secutrelvir in Participants With COVID-19
The main purpose of this study is to compare secutrelvir to placebo with respect to resolution of clinical symptoms in nonhospitalized participants with Coronavirus Disease 2019 (COVID-19) starting intervention within 48 hours of…
- Trial name
- NCT07746544
- Testing
- Secutrelvir
- Where
- Japan
- Volunteers
- 1,200 people
- Sponsor
- Shionogi
COVID-19
Clinical Trial of Immunogenicity Bridging of a Recombinant New Coronavirus（COVID-19） Vaccine (CHO Cell)
Popular topic: A clinical trial comparing the immunogenicity of recombinant New Coronavirus vaccine (CHO cells) among people aged 3 to 17 and 18 to 59 years of age.
- Trial name
- NCT05109598
- Testing
- Recombinant new coronavirus vaccine (CHO cell)
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19
Long-term Follow-up to the Phase 1 Study of Adjuvanted SARS-CoV-2 (SCB 2019) Vaccine for COVID-19.
To develop an effective vaccine against the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, Clover Biopharmaceuticals is conducting a Phase 1 study (CLO-SCB-2019-001) in healthy volunteers to evaluate the…
- Trial name
- NCT04932824
- Testing
- SCB-2019
- Where
- Australia
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
Long COVID
Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.
There are approximately 12 million Americans with COVID-19 Long Hauler Symptoms, including athletes. The symptoms include hypoxemia (low SaO2), fatigue, coughing/sneezing, dyspnea, trouble breathing, body aches, headaches.
- Trial name
- NCT04871815
- Testing
- sodium pyruvate nasal spray
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Cellular Sciences, inc.
Secondary Progressive Multiple Sclerosis
Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)
The purpose of this study was to understand whether participants could mount an immune response to SARS-CoV-2 modRNA vaccines administered either during continuous siponimod treatment or during a treatment break versus while on…
- Trial name
- AMA-VACC (NCT04792567)
- Testing
- BAF312, Baseline disease modifying therapies (DMTs), BNT162
- Where
- 10 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Covid19
Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a
VBI-2902a and VBI-2905a are investigational vaccine candidates that use enveloped virus-like particle (eVLP) expression of a modified version of the SARS-CoV-2 spike (S) glycoprotein and are designed to induce neutralizing…
- Trial name
- NCT04773665
- Testing
- VBI-2902a, VBI-2905a
- Where
- 4 sites in Canada
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
Post-Acute COVID19 Syndrome, Fatigue
Feasibility Study of Adhera® Fatigue Digital Program for Patients With Long COVID-related Fatigue
Adhera® Fatigue Digital Program (or AFDP) is a digital health program based on behavioral and emotional change techniques that provides personalized physical and emotional self-management support for patients with long…
- Trial name
- COVIDAI (NCT05631171)
- Testing
- Adhera® Fatigue Digital Program
- Where
- 2 sites in Spain
- Volunteers
- 58 people
- Sponsor
- Adhera Health, Inc.
Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia
CX-4945 in Viral Community Acquired Pneumonia
This is a Phase II, multi-center, double-blind, randomized, interventional study in approximately 120 subjects to evaluate clinical benefit of CX-4945 in adult outpatients with SARS-CoV-2 and influenza viral infection-associated…
- Conditions
- Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia, Influenza With Pneumonia
- Trial name
- NCT06202521
- Testing
- CX-4945 (SARS-CoV-2 domain), CX-4945 (Influenza virus domain)
- Where
- 7 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Senhwa Biosciences, Inc.
Covid19
Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection
Evelo will investigate the safety and efficacy of EDP1815 in the treatment of patients hospitalized with SARS-CoV-2 Infection
- Trial name
- NCT04488575
- Testing
- EDP1815
- Where
- 4 sites in United States, Turkey (Türkiye)
- Volunteers
- 16 people
- Sponsor
- Evelo Biosciences, Inc.
Covid-19, Protection Against COVID-19
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
Originally, the study was planned to include two parts, i.e., Part A and Part B, however Part B was skipped due to changes in the overall clinical development plan.
- Trial name
- NCT04537949
- Testing
- BNT162b3
- Where
- 2 sites in Germany
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Covid19
Research & Evaluation of LumiraDx SARS-CoV-2 (COVID-19) Point of Care Ab Test
Evaluation of the agreement between fingerstick samples, venous blood, serum and plasma samples when using the LumiraDx SARS-CoV-2 Ab Test against the reference method, using standard qualitative comparison techniques.
- Trial name
- CAPTURE-2 (NCT04597047)
- Testing
- Capillary Collection & Testing, Venous Draw & Testing
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- LumiraDx UK Limited
Covid19, Novel Coronavirus Pneumonia
The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19
Novel coronavirus pneumonia (NCP) and acute respiratory distress syndrome (ARDS) are both associated with the prevailing upper respiratory tract infections caused by the RNA-containing SARS-CoV2 virus of the genius…
- Conditions
- Covid19, Novel Coronavirus Pneumonia, Acute Respiratory Distress Syndrome
- Trial name
- ARDOXSO (NCT04798716)
- Testing
- MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8), MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8), MSC-exosomes delivered intravenously every other day (8:8:8)
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- AVEM HealthCare